文献速递免疫规划卫生政策与健康促进

英格兰和威尔士大规模儿童流感疫苗接种对现有流感疫苗接种规划的影响:模型与成本效果分析

Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis.
PubMed 文献 · Lancet Public Health · 2017-01-01

英格兰和威尔士自2013年起为2-16岁人群资助减毒活流感疫苗规划,本研究用经14个流感季周度就诊和病毒学数据校准的季节性流感传播模型结合经济学评价,计算增量成本效果比。结果显示在£15 000/QALY阈值下低风险老年人接种规划将不再具有成本效果,而在£30 000/QALY阈值下仍具成本效果。

要点

  • 儿童接种时机良好时对低风险老年流感病例的减少程度大于低风险老年人自身接种(若老年人接种率提升较慢)。
  • 高风险人群接种仍具成本效果,低风险老年人接种是否具成本效果存在很大不确定性,取决于成本效果阈值选择。
  • 基础假设下£15 000/QALY阈值时低风险老年人接种规划不再具成本效果,增量成本效果比均值£22 000/QALY,成本效果概率20%。

核心结论

  • 在儿童流感疫苗接种规划存在的情况下,需要重新评估现有基于风险组的疫苗规划的成本效果,尤其考虑到成本效果阈值可能下降。

研究设计与样本

  • 成本效果分析,使用经英格兰和威尔士14个流感季周度就诊和病毒学数据校准的季节性流感传播模型,结合经济学评价计算增量成本效果比(每获得质量调整生命年(QALY)的成本)。

主要发现

  • 若老年人接种率提升较慢,时机良好的儿童接种对低风险老年流感病例的减少程度大于低风险老年人自身接种。
  • 高风险人群接种仍具成本效果;低风险老年人接种是否仍具成本效果存在很大不确定性,取决于成本效果阈值选择。
  • 基础假设下£15 000/QALY阈值时,低风险老年人季节性接种规划的增量成本效果比均值为£22 000/QALY,成本效果概率为20%。
  • 在£30 000/QALY阈值下,该规划仍具成本效果,概率为83%。

关键数值与推荐

  • 基础假设下£15 000/QALY阈值时低风险老年人季节性接种规划的增量成本效果比均值为£22 000/QALY,成本效果概率20%。
  • £30 000/QALY阈值下低风险老年人季节性接种规划仍具成本效果,概率83%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2013 England and Wales began to fund a live attenuated influenza vaccine programme for individuals aged 2-16 years. Mathematical modelling predicts substantial beneficial herd effects for the entire population as a result of reduced influenza transmission. With a decreased influenza-associated disease burden, existing immunisation programmes might be less cost-effective. The aim of this study was to assess the epidemiological effect and cost-effectiveness of the existing elderly and risk group vaccination programme under the new policy of mass paediatric vaccination in England. METHODS: For this cost-effectiveness analysis, we used a transmission model of seasonal influenza calibrated to 14 seasons of weekly consultation and virology data in England and Wales. We combined this model with an economic evaluation to calculate the incremental cost-effectiveness ratios, measured in cost per quality-adjusted life-years (QALY) gained. FINDINGS: Our results suggest that well timed administration of paediatric vaccination would reduce the number of low-risk elderly influenza cases to a greater extent than would vaccination of the low-risk elderly themselves if the elderly uptake is achieved more slowly. Although high-risk vaccination remains cost-effective, substantial uncertainty exists as to whether low-risk elderly vaccination remains cost-effective, driven by the choice of cost-effectiveness threshold. Under base case assumptions and a cost-effectiveness threshold of £15 000 per QALY, the low-risk elderly seasonal vaccination programme will cease to be cost-effective with a mean incremental cost-effectiveness ratio of £22 000 per QALY and a probability of cost-effectiveness of 20%. However, under a £30 000 per QALY threshold, the programme will remain cost-effective with 83% probability. INTERPRETATION: With the likely move to decreased cost-effectiveness thresholds, reassessment of existing risk group-based vaccine programme cost-effectiveness in the presence of the paediatric vaccination programme is needed. FUNDING: National Institute for Health Research, the Medical Research Council.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Hodgson D, Baguelin M, van Leeuwen E, et al. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis. Lancet Public Health. 2017. PMID: 28299371. doi:10.1016/S2468-2667(16)30044-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。